With a new U.S. president, fresh regulations, and shifting deal trends, 2025 is set to be a transformative year for biopharma and healthcare. At Fierce JPM Week 2025, industry leaders will come together to explore what’s next. From market analysis to an examination of evolving regulatory landscapes, this event will provide expert insights into the opportunities and pressing challenges shaping the future of pharma, biotech, and healthcare.
Constant innovation has meant that the pharmaceutical industry has lived with rapid and accelerating change, and as pharma companies have grown, they have come to rely on partners at first for routine tasks, but later to free resources and allow them to focus on science and discovery.
Today, those partners hold responsibility for innovation, acting as catalysts in realizing products for patients. But have these partners ever been so challenged by a universe in chaos? The sector has reached further and further to new modalities, the very definition of pharmaceutical is becoming blurred, and the global geopolitical climate makes everyday delivery challenging.
Hear the perspectives of six senior leaders from some of the industry’s leading partners, including:
John Chiminski, former CEO of Catalent, speaks with Ecolab EVP Hayley Crowe about what it takes to improve manufacturing costs and risk profile while improving sustainability, and Adare CEO Tom Sellig about why oral small molecules have remained an important and attractive market segment
Fierce talks with Bobby Sheng, CEO and Chairman of Bora Pharmaceuticals, about establishing a world-class global CDMO against a backdrop of geopolitical tensions
Later, Kurt Nielsen, Ph.D., principal of Expert Insights, speaks with:
Armin Spura, Ph.D., CEO of BioDuro, about the advantages of choosing a single cRDMo to deliver accelerated translational science, efficient scale-up, and a fast path to first-in-human trials
Darren Head, Chairman & President Bionova Scientific and Board member of Cellipont Bioservices, about running two new CDMOs to bring advanced biologics to clinic, faster
Dan Smithey, Ph.D., CEO of Serán Bioscience, who speaks about solving the most complex oral drug development and manufacturing challenges using innovative approaches and new technologies.
Register for the virtual event here.